The most aggressive subtype of brain tumors is glioma WHO grade IV, the glioblastoma (GBM). The present work aims to elucidate the role of kinin receptors in interactions between GBM cells and mesenchymal stem cells (MSC). The GBM cell line U87-MG was stably transfected to express dsRed protein, single cell cloned, expanded, and cultured with MSC, both in the direct co-cultures (DC) and indirect co-cultures (IC) at equal cell number ratio for 72 h. Up-and down-regulation of matrix metalloproteases (MMP)29 expression in U87-MG and MSC cells, respectively, in direct coculture points to possible MSC participation in tumor invasion. MMP9 expression is in line with significantly increased expression of kinin B1 (B1R) and B2 receptor (B2R) in U87-MG cells and their decreased levels in MSC, as confirmed by quantitative assessment using flow cytometric analysis. Similarly, in indirect cultures (IC), lacking the contact between GBM and MSC cells, an increase of B1 and B2 receptor expression was again noted in U87-MG cells, and no significant changes in kinin receptors in MSC was observed. Functionality of kinin-B1 and B2 receptors was evidenced by stimulation of intracellular calcium fluxes by their respective agonists, des-Arg9-bradykinin (DBK) and bradykinin (BK). Moreover, BK showed a feedback control on kinin receptor expression in mono-cultures, direct and indirect co-cultures. The treatment with BK resulted in down-regulation of B1 and B2 receptors in MSC, with simultaneous upregulation of these receptors in U87-MG cells, suggesting that functions of BK in information flow between these cells is important for tumor progression and invasion. V C
International Society for Advancement of CytometryKey terms Bradykinin; kinin-B1 receptor; kinin-B2 receptor; glioblastoma; bone-marrow mesenchymal stem cells; direct and indirect cell co-culture GLIOMAS, although classified as a rare neoplastic disease, are still the most frequent brain tumors and their most malignant form (WHO stage IV astrocytoma). Glioblastoma (GBM) has an average postoperative survival of only 14.6 or 12.1 months when treated with radio-and chemo-therapy (temozolomide) or with radiotherapy alone, respectively (1). The major characteristic of these tumors is the high infiltration rate of single cells, the so called "guerrilla" cells into the brain parenchyma, even several cm away from the bulk tumor mass. These cells are hard to target by conventional therapies. In view of that, the development of novel therapeutic strategies for successful GBM treatment targeting tumor invasiveness has turned into an aim of priority.